Key result
Cardiac rehabilitation in young patients with nonischemic dilated cardiomyopathy was safe with no adverse events and increased walking distance by a mean of 111 m.
Why the study?
Does cardiac rehabilitation improve cardiometabolic health and safety in young patients with nonischemic dilated cardiomyopathy?
Observational (n=8)
No
Does cardiac rehabilitation improve cardiometabolic health and safety in young patients with nonischemic dilated cardiomyopathy?
Cardiac rehabilitation is feasible, safe, and associated with improved functional capacity and waist circumference in young patients with severe nonischemic dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for cardiac rehabilitation in young nonischemic dilated cardiomyopathy; larger trials needed before practice change.
Nonischemic dilated cardiomyopathy is deadly and costly, and treatment options are limited. Cardiac rehabilitation has proved safe and beneficial for adults with various types of heart failure. Therefore, we retrospectively evaluated the hypothesis that rehabilitation is safe and improves cardiometabolic health in young patients with nonischemic dilated cardiomypathy. From 2011 through 2015, 8 patients (4 males) (mean age, 20.6 ± 6.6 yr; range, 10-31 yr) underwent rehabilitation at our institution. They were in American Heart Association class C or D heart failure and were on maximal medical therapy. Their mean left ventricular ejection fraction at baseline was 0.26 ± 0.15. Two patients had a left ventricular assist device, and 2 were inpatients. To evaluate safety, we documented adverse events during rehabilitation sessions. Clinical endpoints were measured at baseline, immediately after completing rehabilitation, and after one year. Patients attended 120 of 141 possible sessions (85%), with no adverse events. There were no marked changes in mean left ventricular ejection fraction or body mass index. The patients' mean waist circumference decreased by 1.37 ± 0.6 in (n=5; 95% CI, -2.1 to -0.63). Their 6-minute walk distance increased by a mean of 111 ± 75 m (n=5; 95% CI, 18-205). In our small sample of young patients with nonischemic dilated cardiomyopathy, cardiac rehabilitation was feasible and was associated with minimal risk. Our findings suggest that prospective studies in this population are warranted.
No takes yet. Share an insight, caveat, or question.
Wittekind et al. (2018) conducted an observational in Nonischemic dilated cardiomyopathy (n=8). Cardiac rehabilitation was evaluated on 6-minute walk distance (Mean increase 111 m, 95% CI 18-205). Cardiac rehabilitation in young patients with nonischemic dilated cardiomyopathy was safe with no adverse events and increased walking distance by a mean of 111 m.
Synapse has enriched 10 related papers. Consider them for comparative context: